Skip to main content
. 2007 Mar;5(1):19–34. doi: 10.3121/cmr.2007.698

Figure 1.

Figure 1.

Prostanoid hypothesis for the cardiovascular adverse effects of cyclooxygenase (COX)-2 inhibitors. When COX-2 is inhibited, more leukotriene B4 and thromboxane A2 (TXA2) are produced. This tip of balance leads to an increased risk for cardiovascular adverse events.